Navigation Links
New study confirms benefits of treating heart attack patients with a cheap drug
Date:3/30/2014

The initial results of this trial were published a few months ago (Circulation. 2013;128:1495-1503), and showed that patients who received this treatment during emergency transit to hospital had much smaller amounts of dead heart muscle than those randomly assigned to receive no treatment. The new study shows that the proportion of patients with a severely deteriorated heart contractile function is much less (60%) in the group that received metoprolol. Early treatment with metoprolol treatment also significantly reduced the rate of hospital readmission for chronic heart failure, and massively reduced the need to implant a cardioverter-defibrillator.

Borja Ibezjoint lead investigator on the study with Valentn Fusterexplains that "the possibility to reduce so dramatically the number of cases of chronic heart failure (with all the associated treatments and hospital readmissions) with such a cheap procedure (the metoprolol treatment costs less than two euros per patient) could generate enormous savings for health services across Europe."

An initial estimate indicates that if half the heart-attack patients in Europe received early treatment with this cheap drug, the savings in treatment for heart failure alone could exceed 10 billion a year. But as Dr. Fuster is careful to emphasize, it is important to remain cautious, and these estimates will need to be confirmed in a much larger study population across Europe. The research team is already preparing a new clinical trial, with more than 3000 patients in several European countries, which will be powered to demonstrate a reduction in mortality with this treatment. According to the authors, "The results presented today and published simultaneously in this issue of JACC are unprecedented and extremely promising, but rigorous clinical investigation requires corroboration in an independent population." The European consortium for this larger scale study, which will be led from Spain by the CNIC, is already being formed, and includes renowned researchers from Belgium, the Netherlands, Germany, France, Denmark, Serbia, Poland, Sweden, and the United Kingdom.

Dr. Borja Ibez, leader of the Imaging in Experimental Cardiology group at the CNIC and cardiologist at the Hospital Clnico San Carlos, emphasizes that the new study "will be a flagship project for our country that reinforces Spain's international leadership in research into cardiovascular diseases." The CNIC, a center dedicated to the study of cardiovascular diseases, has been led by internationally renowned cardiologist Dr. Valentn Fuster since 2007. Since Dr. Fuster's arrival, the CNIC has become an international reference center, and the leadership of studies such as the one published today demonstrates the high quality of cardiovascular research in our country.

Dr. Gonzalo Pizarro, one of the first authors on the study, comments that "it has been possible to demonstrate the beneficial and sustained effect of this acute treatment thanks to the realization of advanced cardiac magnetic resonance analysis of almost all the patients in this clinical trial." The CNIC is recognized for its expertise and research in different imaging technologies, particularly magnetic resonance imaging. The center runs a range of training programs in cardiovascular imaging in collaboration with the Mount Sinai School of Medicine, which is also directed by Dr. Fuster. Many of the cardiologists who contributed to the design, performance and analysis of the MRI scans in the METOCARD-CNIC trial, including Drs. Pizarro and Fernndez-Friera (joint first authors on the study), received training on these programs, and now work at the CNIC, combining their research activity and their clinical work in the Spanish hospital network.

This is one of the first studies to reveal extraordinary benefits from very early interventionin this case with metoprololduring the first contact with the emergency medical services. Dr. Vicente Snchez-Brunete, a doctor with the ambulance service SUMMA112 and a principal co-investigator on METOCARD-CNIC is in no doubt about the significance of the study, which has "highlighted the importance of the out-of-hospital emergency medical services, which are the first link in the chain of patient care. We have indirect data showing the earlier the patient receives metoprolol during a heart attack, the greater the benefit."

The active participation of the emergency medical services (SUMMA112, 061 Galicia and SAMUR) in METOCARD-CNIC has been voluntary. As Snchez-Brunete explained, "the professionals in the emergency medical services were motivated by the promise of this treatment to change clinical guidelines and the perception that the study was motivated purely by scientific interest."


'/>"/>
Contact: AInhoa Iriberri
airiberri@cnic.es
34-610-295-556
Centro Nacional de Investigaciones Cardiovasculares
Source:Eurekalert

Related medicine news :

1. New study finds strong link between obesity and carb breakdown gene
2. Study compares heart valve systems
3. Study estimates proportion of adults affected by new blood pressure guideline
4. Study finds astronauts hearts become more spherical in space
5. Marriage linked to lower heart risks in study of 3.5+ million adults
6. Study shows promise of preserving fertility in boys with cancer
7. Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses
8. Hormone levels linked to survival of deer calves, study suggests
9. Study identifies key player in motor neuron death in Lou Gehrigs disease
10. Statins could ease coughing in lung disease patients, study finds
11. HPV eradicated by AHCC supplement, preclinical study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: